Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency

New lipid-lowering drugs: an update

(2012) A. S. Wierzbicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effect of Alipogene Tiparvovec (AAV1-LPLS447X) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients

(2012) André C. Carpentier et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Mutations inLPL,APOC2,APOA5,GPIHBP1andLMF1in patients with severe hypertriglyceridaemia

(2012) R. P. Surendran et al.   JOURNAL OF INTERNAL MEDICINE

Niacin: the only vitamin that reduces cardiovascular events

(2011) A. S. Wierzbicki   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency

(2010) Daniel Gaudet et al.   ATHEROSCLEROSIS SUPPLEMENTS

AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells

(2009) F. Mingozzi et al.   BLOOD

Future Challenges for Microsomal Transport Protein Inhibitors

(2009) Anthony Wierzbicki et al.   Current Vascular Pharmacology

Acute Pancreatitis in a Cohort of 129 Patients Referred for Severe Hypertriglyceridemia

(2009) Célia Lloret Linares et al.   PANCREAS

Intramuscular Administration of AAV1-Lipoprotein Lipase S447X Lowers Triglycerides in Lipoprotein Lipase–Deficient Patients

(2008) Erik S. Stroes et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Potential of AAV vectors in the treatment of metabolic disease

(2008) I E Alexander et al.   GENE THERAPY